Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marat Gallyamov"'
Autor:
Murali Kesavan, Danielle Meyrick, Marat Gallyamov, J. Harvey Turner, Sharon Yeo, Giuseppe Cardaci, Nat P. Lenzo
Publikováno v:
Diagnostics, Vol 11, Iss 3, p 515 (2021)
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy (177Lu-PSMA RLT) is an effective salvage treatment.
Externí odkaz:
https://doaj.org/article/0ba78a99ed934bc7923b5dcbd518f731
Autor:
Marat Gallyamov, Igor Gribkov, Aleksandr Inozemtsev, Sergey Toropchin, Jsc 'UEC-Aviadvigatel'
Publikováno v:
Perm National Research Polytechnic University Aerospace Engineering Bulletin. :28-37
The method of advanced bypass turbojet engine core research tests with simulation of target inlet thermogasdynamic parameters at the engine OEM site is considered. It is stated that research testing is traditionally associated with the use of multifu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbdf8427130db2843163071ee12ca651
https://doi.org/10.15593/2224-9982/2021.65.03
https://doi.org/10.15593/2224-9982/2021.65.03
Publikováno v:
Targeted oncology. 16(3)
Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy is emerging as a promising treatment for metastatic castration-resistant prostate cancer refractory to established therapies. While there is an increasing body of surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9248f1c00904de6cd8f51e1b144b3a1a
https://pubmed.ncbi.nlm.nih.gov/33687624
https://pubmed.ncbi.nlm.nih.gov/33687624